Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13207 | 0.91 | L3MBTL3 (0.46) | HRH3L3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL2435401 | 0.89 | L3MBTL3 (0.48) | HRH3L3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL5004416 | 0.88 | KDM2B (0.35) | HRH3L3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL6464543 | 0.84 | HRH3 (0.46) | HRH3L3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL25672747 | 0.83 | L3MBTL3 (0.47) | HRH3L3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL14528417 | 0.82 | L3MBTL3 (0.43) | HRH3L3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL14907095 | 0.80 | L3MBTL3 (0.49) | HRH3L3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL24770316 | 0.77 | KDM4E (0.36) | HRH3L3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL16877337 | 0.77 | L3MBTL3 (0.43) | HRH3L3MBTL3L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL18207732 | 0.77 | SMN1; SMN2 (0.48) | HRH3L3MBTL3L3MBTL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | HRH3 194/4885L3MBTL3 3928/4885L3MBTL1 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.